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Abstract
Background—Progesterone receptor modulators (PRMs) delivered by contraceptive vaginal
rings provide an opportunity for development of an estrogen-free contraceptive that does not
require daily oral intake of steroids. The objective of this proof-of-concept study was to determine
whether continuous delivery of 600–800 mcg of ulipristal acetate (UPA) from a contraceptive
vaginal ring could achieve 80% to 90% inhibition of ovulation.
Study Design—This was a prospective, controlled, open-labeled, multicenter international trial
to examine the effectiveness and safety of this prototype vaginal ring. Thirty-nine healthy women,
21–40 years old and not at risk of pregnancy, were enrolled at three clinic sites. Volunteers
participated in a control cycle, a 12-week treatment period and a post-treatment cycle.
Pharmacodynamic effects on follicular function and inhibition of ovulation, effects on
endometrium, bleeding patterns and serum UPA levels were evaluated.
Results—Mean UPA levels during treatment were nearly constant, approximately 5.1 ng/mL
throughout the study. Ovulation was documented in 32% of 111 “4-week treatment cycles.” A
correlation was observed between serum UPA and degree of inhibition of ovarian activity. There
was no evidence of hyperplasia of endometrium, but PRM-associated endometrial changes were
frequently observed (41%).
© 2012 Elsevier Inc. All rights reserved.
*Corresponding author. Profamilia, Biomedical Research Department, P.O. Box 1053, Santo Domingo, Dominican Republic.
vbrache@gmail.com. .
NIH Public Access
Author Manuscript
Contraception. Author manuscript; available in PMC 2013 May 01.
Published in final edited form as:
Contraception. 2012 May ; 85(5): 480–488. doi:10.1016/j.contraception.2011.10.003.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Conclusion—In this study, the minimum effective contraceptive dose was not established.
Further studies are required testing higher doses of UPA to attain ovulation suppression in a higher
percentage of subjects.
Keywords
Progesterone receptor modulators; Ulipristal acetate; Contraceptive vaginal ring; Ovulation
inhibition; Follicular development; PRM-associated endometrial changes
1. Introduction
Contraceptive prevalence surveys throughout the world reveal high levels of unmet needs
for family planning and of unintended pregnancy [1]. Development of a wider range of safe
and effective contraceptive options with user-friendly, acceptable characteristics has the
potential to reduce unmet need for contraception and may bring additional health benefits to
women. The study presented below indicates one promising route to such a development.
Progesterone antagonists and progesterone receptor modulators (PRMs) represent a class of
progesterone ligands that may exert contraceptive action by different mechanisms. PRMs
have been shown to inhibit ovulation, oppose the proliferation of the endometrium and
induce amenorrhea [2–9]. In a study where the progesterone antagonist mifepristone was
used orally at a low daily dose, ovulation was suppressed in over 90% of the cycles, and
amenorrhea was observed in 65% to 90% of the cycles as well [10].
Several studies have evaluated the contraceptive potential of the PRM ulipristal acetate
(UPA), previously known as VA-2914 or CDB-2914 [11]. UPA is a derivative of 19-
norprogesterone that binds specifically to the human progesterone receptors (PRs) [12]. It is
a potent, orally active modulator of the PR, known to block progesterone action in target
tissues [13]. UPA is devoid of glucocorticoid activity but exhibits a modest
antiglucocorticoid activity, lower than that of mifepristone [14–16]. A single dose of 10–
100 mg of UPA administered with a follicle of 14–16 mm caused a dose-dependent delay in
the time interval from treatment to follicular rupture [17]. When given as emergency
contraception in a single dose of 30 mg in the preovulatory phase, the luteinizing hormone
(LH) peak was postponed, and follicle rupture was delayed [8]. In a study in mice subjected
to gonadotrophin-induced superovulation, the administration of UPA 1 h before human
chorionic gonadotrophin administration resulted in a greater than 90% inhibition of oocyte
release, strongly suggesting a direct effect of the compound upon dominant follicles [7].
Two recent studies confirmed the effectiveness of UPA (30 mg) as an emergency
contraceptive pill [18,19]. Another study evaluating a daily oral administration of UPA has
demonstrated suppression of ovulation and amenorrhea in a majority of women [20]. This
new lead appears to have the potential of being an “estrogen-free” contraceptive with
possibly fewer side effects than contraceptives delivering ethinyl estradiol. It would also
induce amenorrhea, which appears to be both acceptable and beneficial to many women
[21].
The Population Council in collaboration with National Institute of Child Health and Human
Development (NICHD) is developing a 3-month contraceptive vaginal ring (CVR)
containing UPA as a method of estrogen-free hormonal contraception. Contraceptive vaginal
rings offer advantages for drug delivery over those associated with oral administration. After
insertion of a ring into the vagina, steroids are rapidly absorbed by vaginal tissues and pass
into the systemic circulation. Vaginal drug delivery maintains relatively constant blood
levels throughout ring use [22,23] and shows an increased bioavailability of steroids as
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compared with other routes of administration [24]. Additional benefits may result because
CVRs do not require daily attention, and may thus improve compliance. Moreover, rings do
not require a trained provider for insertion and removal, and they are controlled by the users
[25,26].
A Phase 1 study of a CVR releasing 400–500 mcg per day of UPA (CDB-2914) was
previously completed in 12 women [27]. CVR delivery of UPA permitted rapid absorption
into the blood stream. UPA serum levels reached a plateau of 2–3 ng/mL within 72 h of ring
insertion and remained at that level for the 1-month duration of the study. However,
ovulation was suppressed in only 3 out of 12 subjects, indicating an insufficient dose of the
PRM.
Based on those results, a new ring delivering a higher dose of UPA was designed and tested
in a 3-month proof-of concept study. The main objective was to determine whether the
continuous delivery of 600–800 mcg of UPA could achieve 80% to 90% inhibition of
ovulation and induce amenorrhea in a similarly high proportion of women. The effect of this
form of administration of UPA upon the endometrium was also evaluated as a key objective.
2. Method and materials
This prospective, open-labeled, three-center trial was conducted at Instituto Chileno de
Medicina Reproductiva in Santiago, Chile; at USC Los Angeles, CA; and PROFAMILIA in
Santo Domingo, Dominican Republic, in accordance with the guidelines of the Declaration
of Helsinki. Approval was granted by the Ethics Committee of each center and by the
Institutional Review Board of the Population Council (NY).
After providing informed consent, 39 healthy women, 13 at each center, were tested for
normal ovulatory function and then initiated use of the ring. The subjects were 21 to 40
years old, with regular menstrual cycles of 25 to 35 days’ duration and a body mass index
(BMI) <31. The women were not breastfeeding, had no contraindications to the use of oral
contraceptives and were protected from pregnancy by sterilization of either partner,
abstinence or consistent use of barrier methods.
The CVR studied is of a matrix design composed of micronized UPA mixed in a silicone
rubber matrix. An external layer made of a silicone elastomer membrane served as a rate-
limiting barrier, producing a near zero-order delivery rate of UPA. This flexible ring is 59
mm in diameter with ring body cross-section of 8.4 mm and an expected release rate of 600–
800 mcg/day of UPA.
The study required a baseline control cycle to confirm normal ovulatory cycles, followed by
12 weeks of continuous ring use and a follow-up cycle to document return of ovulation. For
analysis, each 4-week period of the 12 weeks of ring use was considered a “treatment
cycle”; therefore, each participant contributed three treatment cycles for analysis.
2.1. Ovarian function
Ovarian function during ring use was assessed twice weekly by determination of estradiol
(E2) and progesterone (P) serum concentrations and by vaginal ultrasounds. Whole blood
was obtained during the morning and allowed to stand at room temperature for at least 1–2
h. The clotted whole blood was separated to obtain serum aliquot specimens of
approximately 1 mL and frozen at −20°C. In Chile, estradiol and progesterone
concentrations were measured by radioimmunoassay (DPC, Diagnostic Products
Corporation, Los Angeles, CA, USA) with sensitivities of 21 pmol/L and 0.2 nmol/L,
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respectively, and interassay coefficients of variation (CVs) of 6.8%–9.3% for E2 and 5.9%–
6.3% for P.
In the Dominican Republic, an electrochemiluminescence immunoassay (Roche Elecsys
2010, Mannheim, Germany) with sensitivities of 18 pmol/L and 0.1 nmol/L, respectively,
and interassay CVs of 2.3%–6.2% for E2 and 3.7%–5.5% for P was used. At the Los
Angeles site, estradiol was measured in serum by radioimmunoassay following extraction
with ethyl acetate:hexane (3:2) [28] with an assay sensitivity of 10 pg/mL and an interassay
CV of b10%. Serum progesterone levels for this site were measured by a competitive
chemiluminescent immunoassay on the Immulite analyzer (Siemens Medical Solutions
Diagnostics, Malvern, PA, USA) with a sensitivity of 0.2 ng/mL and an average interassay
CV of 10.6%.
Transvaginal ultrasounds (TVUs) to evaluate follicular development were performed by a
single individual at two sites at each semiweekly visit. In those centers, TVU was performed
with a real-time scanner, Shimadzu SDU-400, using a 4–8-MHz vaginal transducer, or with
a Medison Co. Ltd. SA 6000 ultrasound system, using a 7.5-MHz vaginal transducer. At the
third site, semiweekly measurements of follicles were made by rotating staff members.
Measurements proved frequently incompatible with preceding and succeeding follicular
size. Accordingly, no follicular measurements from this site were used in this analysis.
Ovarian function was examined over five time periods: (1) a control cycle prior to ring
initiation to establish eligibility; (2) weeks 1–4 of ring use (treatment cycle 1); (3) weeks 5–
8 of ring use (treatment cycle 2); (4) weeks 9–12 of ring use (treatment cycle 3) and (5) a
post-treatment cycle to establish return to normal menstruation. The analyses presented
focus on the treatment period.
Two sets of data were used to categorize ovarian function. Treatment cycles from all three
centers were classified according to the presence or absence of luteal activity, defined as
P≥10 nmol/L in at least two samples.
A second ovarian function classification was employed based on both ultrasound and
endocrine profiles observed in each “treatment cycle.” The following six classifications
were used: (1) ovulation (follicular rupture immediately followed by an elevation of serum
progesterone concentration that reached 10 nmol/L or more in at least two consecutive
samples); (2) ovulatory dysfunction (a follicle ≥30 mm at rupture and preceded by
progesterone levels ≥10 nmol/L); (3) luteinized unruptured follicle (LUF) (no follicular
rupture but more than one P level ≥5 nmol/L); (4) persistent follicle (follicle ≥15 mm for ≥7
days without rupture or P increase); (5) no follicular development: no follicle >12 mm and
(6) no follicular resolution (follicle development ≥10 mm with no resolution in the
“treatment cycle”).
2.2. Serum UPA measurements
Serum levels of UPA were measured once a week during the 12 weeks of ring treatment.
The serum samples were analyzed by radioimmunoassay developed at the Population
Council according to the method of Larner et al. [12]. To correlate ovarian activity with
UPA serum levels, mean levels of the weekly UPA samples taken during each “treatment
cycle” were calculated.
2.3. Endometrial biopsies
An endometrial biopsy was taken by a Pipelle in the luteal phase of the control cycle prior to
treatment (7–9 days following ovulation) and at the end of 12 weeks of treatment, when the
ring was withdrawn. Endometrial biopsy specimens were fixed in formalin and processed in
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paraffin wax by standard methods in the local center laboratories. Paraffin-embedded tissue
blocks were sent to the Edinburgh University Pathology Department in batches, and 3-μm
sections were cut by standard microtomy for hematoxylin and eosin staining and for
immunohistochemical assessment of proliferation markers. Preinsertion biopsies were
assessed microscopically and categorized according to standard histological criteria, as
described in Blaustein’s Pathology of the Female Genital Tract [29]. The end of treatment
biopsies were assessed in the same way, but additional categories were used to take into
account histological appearances that were evident in these biopsies. Appearances were
categorized as inactive, proliferative or secretory, with a further subdivision of glandular
architecture as normal or disordered. The term “disordered glandular architecture” was used
to describe glands in which there was tortuosity of the normal gland structure. Recently,
typical changes of the endometrium as observed here under the action of PRMs have been
described as PRM-associated endometrial changes (PAECs) [30].
2.4. Proliferation markers
Immunohistochemical assessment of proliferation markers Ki-67 and phosphorylated
histone protein 3 (PH3) was performed using mouse monoclonal antibody MIB-1 (Dako,
Glostrup, Denmark) and Phospho-H3 (Upstate Cell Signalling Solutions, Charlottesville,
VA, USA) 1:3200. Briefly, fresh 3-μm sections were dewaxed and submitted to antigen
retrieval by immersion in Tris-EDTA (pH 8) and pressure cooked for 2.5 min at 1 m bar.
Primary antibody was applied at 1 in 200 dilution (Ki-67) and 1 in 3200 (PH3). Negative
control sections were performed in which the primary antibody was omitted. Tonsil or
normal proliferative phase endometrium was used as positive control tissues. After
incubation of primary antibody for 30 min, sections were washed, and the Dako EnVision-
HRP visualization system was used (Dako), after which slides were counterstained with
hematoxylin and mounted conventionally. For both markers, staining was assessed
semiquantitatively for the three endometrial compartments (glandular epithelium, surface
epithelium and stroma).
2.5. Safety
Clinical chemistries were evaluated prior to ring use and upon completion of treatment.
Fasting blood samples were obtained during the screening visit, on the last day of ring use
(treatment) and on the termination visit scheduled after the first spontaneous menses post
ring use. Measurements included a complete clinical chemistry, complete blood count,
amylase, prolactin, prothrombin time and cortisol. Urinalyses were also performed during
these visits.
Diary cards were provided to subjects at the beginning of each cycle to record bleeding
patterns and adverse events, if any.
2.6. Statistical methods
Each participant contributed three treatment cycles for analysis. Under the assumptions that
the ring would prove 90% successful in inhibiting ovulation and 34 women would complete
the study, 102 cycles would be analyzed. Under this null hypothesis, the probability of
observing between 86 and 97 nonovulatory cycles (84% to 95.1%) would be 95.5%.
Interpreting the null hypothesis to mean that the UPA ring would prove successful in
preventing 90% of the women from ovulating during all three of their treatment cycles, one
would expect to observe between 27 and 33 successes out of 34 subjects completing the
study treatment. To account for possible early withdrawals and loss to followup, each clinic
enrolled 13 women, a total of 39 subjects.
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Data and analyses are presented only for the 37 women who completed the 12-week
treatment period. Standard measures have been used for descriptive statistics. Statistical
significance was set as p≤.05. Both parametric and nonparametric two-sided tests were
employed as indicated in the text and tables. These include paired (t, Wilcoxon) and
unpaired tests (t, Mann–Whitney), analysis of variance tests (F, Kruskal–Wallis), post hoc
comparison and χ2 tests.
Additionally, we examined the sequence of UPA levels by week for each woman and
computed Spearman (nonparametric) and Pearson correlation coefficients to measure the
direction and magnitude of the trend for every subject.
3. Results
Thirty-seven women completed the study. Two volunteers discontinued early, citing
personal reasons. The mean age and gravidity of participants who completed the study were
35.3±4.4 years (±SD) and 3.1±1.2, respectively. The mean body weight and BMI were
62.4±10.2 kg and 25.4±3.1 kg/m2, respectively. Participants from Chile were significantly
older, while body weight and BMI were lowest in the Dominican Republic and highest in
Los Angeles (Table 1).
3.1. Ovarian activity
Table 2 summarizes the frequency of treatment periods with luteal activity for all three
centers over the three successive “treatment cycles.” Luteal activity (as determined by P≥10
nmol/L in at least two samples) was observed in almost half of the 111 “treatment cycles.”
There were significant differences between clinics, with the highest frequency of luteal
activity reported in the Dominican Republic and the lowest in Chile. Seven women at the
Santiago site and two in Los Angeles exhibited no rise in P>9.9 nmol/L in any treatment
cycle. The other 28 women had elevated P levels ≥10 nmol/L at least once in the 12-week
treatment period.
Table 3 shows ovarian activity in six-category classification based upon both hormonal and
ultrasound data at two centers during 78 “UPA treatment cycles.” Thirty-two percent of the
78 treatment periods were classified as ovulatory, while LUF occurred in 13%. Persistent
follicles were observed in 31% of the periods, and there was no follicular development in
9% of the “cycles.” Significant differences in distribution of categories were observed by
clinic. Follicular development occurred in all women during the study; the few cycles with
no follicular development were temporary and not maintained for two consecutive treatment
periods. Estradiol levels fluctuated within the normal range in all ultrasound classifications,
except for lower estradiol levels (in the range of early follicular phase) observed in the no
follicular development category (mean highest E2 level 178±71 pmol/L).
3.2. UPA serum levels
Mean UPA levels over all cycles of treatment were nearly constant, approximately 5.1 ng/
mL throughout the study (Fig. 1). Mean UPA serum levels were slightly higher in Chile,
with levels ranging from 5.3 to 5.9 ng/mL per treatment cycle, whereas mean levels of 5.0 to
5.1 ng/mL were maintained at the Dominican Republic clinic. In Los Angeles, UPA
concentrations decreased slightly from around 4.7 ng/mL in the first two treatment cycles to
4.4 ng/mL in the last treatment cycle (p<.02, paired tests).
As shown in Table 2, mean UPA levels differed significantly per clinic and were
significantly lower in the cycles with luteal activity. A correlation was observed between
serum UPA and the different classifications of ovarian activity based on both ultrasound and
hormonal data (Table 3). As anticipated, the highest UPA levels were observed in cycles
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with the highest degree of inhibition of ovarian activity: no follicular development (7.6±1.3
ng/mL), while the lowest UPA levels were observed in ovulatory cycles (4.7±0.9 ng/mL).
Over all categories, the differences in UPA levels by category proved significant (p<.0001).
3.3. Endometrial tissue evaluation
Histological assessment of pre- and post-treatment endometrial biopsy specimens taken
from trial participants was performed by a gynecological pathologist (A.W.) with previous
experience of effects of PRMs and antiprogestins on endometrium. A total of 36
pretreatment biopsies taken between days 19 and 29 of the control cycles were received. All
except two specimens showed normal appearances of the secretory phase of the menstrual
cycle; one was insufficient for histological assessment, and the remaining one showed
appearance of chronic endometritis detected in a subject without any symptomatology and
which disappeared without treatment in the biopsy taken at the end of treatment.
End of treatment biopsy specimens were obtained from 37 women after 12 weeks of
continuous use of the UPA ring delivering 600–800 mcg/day. There was no evidence of
hyperplasia of endometrium of either simple or complex types, and there was no evidence of
cytological atypia. Cystic dilatation of glands was not commonly seen, but an inactive
appearance was seen in many cases where tubular glands were widely interspersed with
compact stroma. Fourteen women had end of treatment endometrial biopsies classified as
“inactive,” 17 were proliferative, and 6 were secretory. However, benign glandular changes,
described as PAECs, were frequently observed (41%) in a background of inactive or weakly
proliferative endometrium. The percentage of endometrial biopsies that showed benign
glandular changes was significantly greater among cycles with no luteal activity in the
preceding 60 days (59%) as compared with those with luteal activity in the same period
(25%) (Table 4).
Immunohistochemical staining with proliferation marker Ki-67 showed a significant
increase in the glandular epithelium post-treatment (Fig. 2). In pretreatment luteal phase
biopsies, as expected, Ki-67 expression was absent from glandular epithelial cells but was
expressed at relatively low levels in stromal cells. Post-treatment, there was a significant
increase in Ki-67 staining in the glandular and surface epithelium, but no significant change
in expression was seen in the stroma. The mitotic marker PH3 showed a significant increase
in activity in glands and surface epithelium post-treatment, but not much change in the
stroma.
3.4. Bleeding patterns
The mean number of bleeding onsets during the 12 weeks of treatment was 1.19, while the
mean number of bleeding and spotting onsets was 1.41. These values are significantly below
the minimum expected value of two onsets in the three 4-week periods (p<.05).
The mean days of bleeding and of bleeding and spotting in the 12 weeks of ring use for all
37 subjects were, respectively, 4.16 and 7.51. These overall values are about 33% to 50% of
what one may expect over a 12-week period in normally menstruating women. The Santiago
clinic had the lowest average number of days with a bleeding and/or spotting event.
Progesterone increase and drop were followed by a withdrawal bleeding with few
exceptions (4/51).
3.5. Adverse events
A variety of minor conditions were reported throughout treatment; the most frequent were
headache (60%), common cold symptoms (32%) and leukorrhea (19%). All of these events
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were considered mild or of moderate intensity. No events were considered probably related
to the study drug. Leukorrhea was classified as possibly related to ring use or to high E2
levels in some subjects.
One serious adverse event (SAE), mild hyperthyroidism, was reported. However, levels of
thyroid stimulating hormone, T3 and T4 were measured on a remaining aliquot of a baseline
serum sample from the subject and were indicative of a preexisting subclinical
hyperthyroidism at enrollment. Therefore, the SAE was not related to the study drug.
Blood pressure remained steady throughout the study, with no significant change in either
systolic or diastolic blood pressure. Of more than 20 clinical chemistry and hematological
parameters studied, two showed statistically significant changes in means by paired analysis,
but none showed clinically relevant changes or marked increased over normal values (Table
5). Total cholesterol increased over baseline during treatment (171.6 vs. 178.9 mg/dL),
while calcium levels decreased (9.1 vs. 8.9 mg/dL).
4. Discussion
The current study tested the effects on ovarian activity and menstrual bleeding of 600–800
mcg/day of UPA released from a newly formulated vaginal ring. Ovulation, as judged by
ultrasound and hormonal data, was observed in one third of the treatment periods. Thus, the
present ring formulation seems more effective for preventing ovulation than previously
tested rings releasing lower dosages of UPA, but is not yet the fully effective dose. This is in
agreement with UPA serum levels attained with this ring which were around 5 ng/mL, with
a higher rate of ovulation suppression when levels reached or surpassed 7 ng/mL.
The observation of higher UPA levels among Chilean women cannot be explained by a
difference in BMI, as BMI was similar in all three clinics. We cannot completely exclude
the possibility of difference in compliance between centers. Although women were
instructed to not remove the ring during the study, this might have occurred. However, the
UPA levels per participant at each center were very constant during the study, and the
presence of the ring in the vagina was assessed twice a week at each visit. If women were
inserting the ring only for their visits, a much larger variability in UPA serum levels would
have been observed. The possibility of a random difference cannot be excluded.
By comparing the rate of ovulation suppression attained with rings differing in their rate of
release of UPA or by comparing the same ring tested in different women, a good dose–
response relationship becomes quite apparent. A correlation was observed between UPA
serum levels and the degree of ovulation inhibition. The highest UPA levels were observed
in cycles with no follicular development, while the lowest levels were observed in ovulatory
cycles. With oral doses, ovulation suppression in 80% of subjects has been observed with
serum levels above 10 ng/mL [20]. Animal model studies have demonstrated a dose–
response relationship between UPA and ovulation suppression [31]. A similar trend has been
observed with oral doses administered to healthy female volunteers [17,20]. In any event,
the potential for delivering UPA by a vaginal ring has been demonstrated, although its use
for contraception will require higher delivery rates of the PRM in the ring design.
All periods characterized by persistent follicle and LUF had elevated E2 circulating levels
typically associated with a growing dominant follicle destined to ovulate. This suggests
normal gonadotropin stimulation during the follicular phase. The mechanism by which UPA
prevented follicular rupture in 67% of cycles may be a direct effect of this PRM upon the
ovary, as demonstrated in rodents deprived of the PR [7] or by blocking the onset of the LH
surge. When given as emergency contraception in a single dose of 30 mg in the preovulatory
phase, the LH peak was postponed, and follicle rupture was delayed [8]. Low daily doses of
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the antiprogestin mifepristone were shown to suppress the preovulatory surge of LH [10].
Chabbert-Buffet et al. [20] report little effect on gonadotropin with the PRM oral UPA at
doses up to 10 mg, but they took twice a week blood sampling, which is not sufficient to
detect the LH surge.
The endometrial changes were in line with those described with other PRMs [30]. In April
2006, an NICHD workshop convened a group of pathologists to define the histological
appearances of PRM-treated endometrium and to develop new terminology [32]. Overall, a
‘class effect’ was noted, designated as PAECs [30]. There was no evidence of hyperplasia or
cytological atypia in any of the endometrial biopsies. Expression of proliferation markers
Ki-67 and PH3 was significantly increased in post-treatment endometrial glandular
epithelium compared to baseline, but baseline biopsies were taken during the secretory
phase, when proliferative activity is at very low levels.
Headache, common cold symptoms and leukorrhea were reported most frequently. No
significant changes in systolic or diastolic blood pressure or biochemical and hematological
parameters were reported. This is consistent with the findings reported in other studies
[20,27].
In the current study, the minimum effective contraceptive dose was not established, and only
the women with serum levels around 6–7 ng/mL experienced ovulation suppression. In those
women, the changes of the endometrium reflected the effect of the PRM without the
presence of P. Further studies are required testing higher doses of UPA to attain ovulation
suppression in a higher percentage of subjects. Long-term follow-up studies of the
endometrium are warranted.
Following the Woman’s Health Initiative study publication, it was suggested that the use of
some progestins may increase the risk of breast cancer [33]. Later on, it was shown that
various synthetic progestins combined with estrogen increased the risk of breast cancer,
while the use of natural P did not [34]. Therefore, it has been suggested that the use of a
PRM inhibiting the PR might also suppress proliferation of mammary gland cells and
possibly decrease the risk for breast disease. Although this hypothesis remains to be
demonstrated, the possibility of adding a major health benefit to a new contraceptive method
would be a welcome addition [35].
Given the good tolerability of PRMs, and their capacity to inhibit ovulation without
suppression of the endogenous E2 secretion, this category of compounds represents a novel
and promising approach to contraception without synthetic estrogens.
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Fig. 1.
Mean UPA serum levels per site during 12 weeks of treatment.
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Fig. 2.
Immunohistochemical assessment of the proliferation marker Ki-67 pre- and post-treatment
of UPA. The summary chart shows mean Ki-67 histoscore, a semiquantitative score
allocated to each endometrial compartment — glands, surface epithelium and stroma —
according to the percentage of nuclei showing positive staining. Ki-67 gland histoscore=%
of glands stained×nuclear score (NS) (NS: 0=no staining; 1=b10% of nuclei show staining
in positively stained glands; 2=10%–50%; 3=N50%). Surface epithelium histoscore=%
surface epithelial cells showing staining. Stroma histoscore=% stromal cells showing
staining. Note that histoscore values allow comparison of Ki-67 labeling between pre- and
post-treatment states, but not comparison between compartments.
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Table 4
Correlation of ovulatory status and presence of PAECs in the histological appearance of the endometrium after
12 weeks of treatment
Ovulatory status Normal glandular
architecture
n (%)
PAEC benign
glandular changes
n (%)
Total
Luteal activity (P>10
nmol/L) in preceding
60 days
15 (75%) 5 (25%) 20
No luteal activity in
preceding 60 days
7 (41%) 10 (59%) 17
Total 22 (59%) 15 (41%) 37
χ2 test, p=.0368; Fisher’s Exact Test one-sided, p=.0394; Fisher’s Exact Test two-sided, p=.0498.
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Table 5
Paired analysis of changes in clinical chemistry
Measure Units Admission End of treatment p
Mean±SD
Hematocrit % 39.1±3.2 39.3±2.8 .6117
Hemoglobin g/dL 13.1±1.2 13.1±1.2 .8404
Glucose mg/dL 80.2±7.7 78.7±7.6 .1396
Uric acid mg/dL 3.3±0.8 3.5±0.8 .0655
BUN mg/dL 10.7±3.0 11.1±3.4 .3741
Creatinine mg/dL 0.72±0.10 0.7±0.1 .2889
GGT U/L 13.8±8.7 13.6±9.1 .7874
ALT/SGPT U/L 15.5±6.8 15.9±7.6 .7661
AST/SGOT U/L 17.8±5.2 19.2±5.4 .1905
LDH U/L 247.1±162.6 236.0±140.6 .0549
Alk phos U/L 58.8±20.0 58.4±18.0 .8291
T bilirubin mg/dL 0.6±0.3 0.6±0.3 .0914
Total protein g/dL 7.2±0.4 7.2±0.5 .5377
Albumin g/dL 4.2±0.3 4.2±0.3 .4518
A/G ratio 1.4±0.2 1.4±0.2 .8140
Cholesterol mg/dL 171.6±31.0 178.9±30.4 .0355
Triglyceride mg/dL 86.0±36.1 92.5±40.9 .1676
Amylase U/L 87.3±45.4 89.3±46.0 .1721
Sodium nmol/L 140.4±1.9 140.2±1.6 .3265
Potassium nmol/L 4.1±0.4 4.2±0.3 .1123
Chloride nmol/L 103.4±6.5 103.7±2.0 .4038
Calcium mg/dL 9.1±0.5 8.9±0.4 .0027
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